118.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
AmBisome Market 2025 Is Booming Worldwide by 2032 |Gilead Sciences Inc and Astellas Pharma Inc - openPR.com
Using data tools to time your Gilead Sciences Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Is Gilead Sciences Inc. stock cheap at current valuation2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com
François Cherifi: Deeply Grateful to Gilead Sciences for Awarding me the Gilead Scholarship at ESMO2025 - Oncodaily
Exit strategy if you’re trapped in Gilead Sciences Inc.July 2025 Gainers & Growth Focused Entry Reports - newser.com
Is this a good reentry point in Gilead Sciences Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Is Gilead Sciences Inc. stock attractive for long term wealth buildingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Gilead Sciences’ GS-1219 HIV Study Update: Implications for Investors - TipRanks
What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView
Will Gilead Sciences Inc. stock remain a Wall Street favoriteMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
Gilead Sciences: Strong Market Position and Growth Potential in HIV and PrEP with Promising Yeztugo Launch - TipRanks
Will Gilead Sciences Inc. stock sustain high P E ratiosJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitMarket Rally & High Accuracy Trade Signal Alerts - newser.com
Will Gilead Sciences Inc. outperform the marketEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Is Gilead Sciences Inc. still worth holding after the dip2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com
Gilead Sciences VP Praises China's Reforms for Helping Launch More Novel Drugs - Yicai Global
Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a buy for dividend portfolios2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsPortfolio Risk Summary & Real-Time Market Trend Scan - newser.com
How to build a dashboard for Gilead Sciences Inc. stockShare Buyback & Daily Profit Focused Screening - newser.com
Using economic indicators to assess Gilead Sciences Inc. potential2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
Is Gilead Sciences Inc. (GIS) stock inflation resilientEarnings Summary Report & Verified High Yield Trade Plans - newser.com
Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics - Markets Mojo
Florida Settlement with Gilead Sciences for Improper Promotion of HIV Drugs - West Orlando News
Chart based exit strategy for Gilead Sciences Inc.Market Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Gilead Sciences Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Morgan Stanley Remains Bullish on Gilead Sciences (GILD) - MSN
What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com
TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 - GuruFocus
Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe
Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener
TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener
Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com
Gilead to present liver disease data at AASLD conference - StreetInsider
(Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire
CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus
Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus
Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha
Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):